CN110327319A - A kind of drug and preparation method thereof for treating neurodermatitis - Google Patents
A kind of drug and preparation method thereof for treating neurodermatitis Download PDFInfo
- Publication number
- CN110327319A CN110327319A CN201910621479.3A CN201910621479A CN110327319A CN 110327319 A CN110327319 A CN 110327319A CN 201910621479 A CN201910621479 A CN 201910621479A CN 110327319 A CN110327319 A CN 110327319A
- Authority
- CN
- China
- Prior art keywords
- drug
- neurodermatitis
- treatment
- vitamin
- chlorpheniramine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a kind of drug and preparation method thereof for treating neurodermatitis, is related to field of medicaments.A kind of drug for treating neurodermatitis, including following components according to parts by weight: 0.01~0.5 part of vitamin B complex, 0.05~0.3 part of calcium colloidal et vit D, 0.003~0.01 part of chlorpheniramine, 0.001~0.005 part of dexamethasone acetate, 0.002~0.008 part of Triamcinolone acetonide.The drug for the treatment of neurodermatitis can be obtained by mixing above-mentioned component.The drug of this treatment neurodermatitis is applied alone better than drug.The drug of the treatment neurodermatitis obtained after mixing has synergistic effect, there is antiallergy, detumescence, antipruritic and other effects.The drug of existing treatment neurodermatitis mainly includes external application and takes orally, and treatment cycle is long, slow effect.Compared with existing drug, it is provided by the invention treatment neurodermatitis drug have many advantages, such as treatment cycle it is short, it is quick, prepare it is convenient.
Description
Technical field
The present invention relates to field of medicaments, in particular to a kind of drug and preparation method thereof for treating neurodermatitis.
Background technique
Neurodermatitis is also known as lichen simplex chronicus, is a kind of slow characterized by skin lichenification and violent itch
Property diseases associated with inflammation, it is considered that the occurrence of this disease may be cerebral cortex inhibit and excited dysfunction caused by, it is nervous,
Anxiety, depression, local stimulation (such as friction, hidrosis) and indigestion drink, feed and pungent can induce or aggravate this
Disease.Currently, the drug of existing treatment neurodermatitis mainly includes external application and takes orally, treatment cycle is longer.
Summary of the invention
The purpose of the present invention is to provide a kind of drug for treating neurodermatitis, the drug of the treatment neurodermatitis is controlled
The treatment period is shorter, and significant effect.
Another object of the present invention is to provide a kind of preparation method of drug for treating neurodermatitis, this preparation methods
Process is simple, easy to operate, can be mass-produced.
The present invention solves its technical problem and adopts the following technical solutions to realize.
The present invention proposes a kind of drug for treating neurodermatitis, including following components according to parts by weight:
0.01~0.5 part of vitamin B complex, 0.05~0.3 part of calcium colloidal et vit D, 0.003~0.01 part of chlorpheniramine, acetic acid
0.001~0.005 part of Sai meter Song, 0.002~0.008 part of Triamcinolone acetonide.
The present invention proposes a kind of preparation method of the drug of above-mentioned treatment neurodermatitis comprising: by vitamin B complex,
The drug for treating neurodermatitis can be obtained in calcium colloidal et vit D, chlorpheniramine, dexamethasone acetate, Triamcinolone acetonide mixing.
The drug and preparation method thereof of the treatment neurodermatitis of the embodiment of the present invention at least has the advantages that
The present invention provides a kind of drug for treating neurodermatitis, including following components according to parts by weight: vitamin B
0.01~0.5 part of race, 0.05~0.3 part of calcium colloidal et vit D, 0.003~0.01 part of chlorpheniramine, dexamethasone acetate 0.001~
0.005 part, 0.002~0.008 part of Triamcinolone acetonide.By by vitamin B complex, calcium colloidal et vit D, chlorpheniramine, fill in rice to acetic acid
Pine, Triamcinolone acetonide are mixed to get the drug for the treatment of neurodermatitis.The drug therapy period of this treatment neurodermatitis is short, is better than
Drug is applied alone.The drug of the treatment neurodermatitis obtained after mixing complements each other in effect, has synergistic effect, there is anti-mistake
Quick, repellent antipruritic, relieve the wind syndrome stop stem and other effects.There is good therapeutic effect to treatment neurodermatitis, and significant in efficacy, cures
It does not recur afterwards, safe without toxic side effect, can achieve the purpose that treating both manifestation and root cause of disease, be suitble to clinical use.By mixing, make raw material at
/ mutually fusion, preparation process is simple, easy to operate, can be used directly after preparing.Existing treatment neurodermatitis
Drug mainly include external application and for oral administration, treatment cycle is long, slow effect.It is provided by the invention to control compared with existing drug
Treat neurodermatitis drug have many advantages, such as treatment cycle it is short, it is quick, prepare it is convenient.
Specific embodiment
It in order to make the object, technical scheme and advantages of the embodiment of the invention clearer, below will be in the embodiment of the present invention
Technical solution be clearly and completely described.The person that is not specified actual conditions in embodiment, according to normal conditions or manufacturer builds
The condition of view carries out.Reagents or instruments used without specified manufacturer is the conventional production that can be obtained by commercially available purchase
Product.
The drug and preparation method thereof of the treatment neurodermatitis of the embodiment of the present invention is specifically described below.
The present invention proposes a kind of drug for treating neurodermatitis, including following components according to parts by weight:
0.01~0.5 part of vitamin B complex, 0.05~0.3 part of calcium colloidal et vit D, 0.003~0.01 part of chlorpheniramine, acetic acid
0.001~0.005 part of Sai meter Song, 0.002~0.008 part of Triamcinolone acetonide.
By the way that vitamin B complex, calcium colloidal et vit D, chlorpheniramine, dexamethasone acetate, the above-mentioned component of Triamcinolone acetonide are mixed
To the drug for the treatment of neurodermatitis.The drug therapy period of this treatment neurodermatitis is short, is applied alone better than drug.Each raw material phase
It is auxiliary to coordinate, there is synergistic effect.Vitamin B complex and calcium colloidal et vit D, to alleviate neurodermatitis, can play battalion with antiallergy
Repose through effect.Dexamethasone acetate and chlorpheniramine have anti-inflammatory, anti-allergic effects, can inhibit the hyperplasia of connective tissue, drop
Low capillary vascular wall and permeability of cell membranes reduce inflammatory seepage discharge, inhibit the formation of histamine and other toxicants and release
It puts.Triamcinolone acetonide has anti-inflammatory, antipruritic and pressor effect.By mixing, merge above-mentioned each ingredient mutually, it can
Make each position targeted therapy, to achieve the effect that alleviate neurodermatitis and antipruritic.Treatment nerve skin provided by the invention
Scorching medicine preparation process is simple, abundant raw material, has many advantages, such as antiallergy, repellent antipruritic, anti-inflammatory.
Wherein, vitamin B complex includes vitamin B12 and/or vitamin B1.Vitamin B12 and/or vitamin B1 add
Add, the anti-allergic effects that collaboration increases the drug for the treatment of neurodermatitis can be played with other raw materials.
Wherein, according to the drug of above-mentioned treatment neurodermatitis, including following components according to parts by weight:
0.2 part of vitamin B12,0.1 part of calcium colloidal et vit D, 0.005 part of chlorpheniramine, 0.003 part of dexamethasone acetate, song
0.005 part of An Naide.
Vitamin B12, calcium colloidal et vit D, chlorpheniramine, dexamethasone acetate, Triamcinolone acetonide based on above-mentioned parts by weight is mixed
The drug of the treatment neurodermatitis obtained after conjunction, treatment cycle is shorter, quick, can be used as disposable, avoids wasting.
Further, the drug of above-mentioned treatment neurodermatitis further includes hydrocortisone 0.001 according to parts by weight
~0.008 part.Hydrocortisone has immunosuppressive action, antitoxic action and anti-inflammatory effect.Hydrocortisone, chlorpheniramine, vinegar
The anti-inflammatory effect of the drug for the treatment of neurodermatitis can be effectively improved after sour dexamethasone mixing.
Further, the drug of above-mentioned treatment neurodermatitis further include cetirizine 0.002 according to parts by weight~
0.01 part.Chlorpheniramine in cetirizine and raw material can shorten the drug for the treatment of neurodermatitis collectively as antiallergic
Treatment cycle.
Further, the drug of above-mentioned treatment neurodermatitis further include doxepin 0.005 according to parts by weight~
0.0125 part.Pruritis can effectively be mitigated after doxepin and Triamcinolone acetonide mixing, keep its skin lesion thinning.
Further, the drug of above-mentioned treatment neurodermatitis further include lidocaine 0.005 according to parts by weight~
0.01 part.Lidocaine and Triamcinolone acetonide can play the role of jointly it is anti-inflammatory, relieve the pain.
Wherein, the dosage form of the drug of above-mentioned treatment neurodermatitis includes injection.
The embodiment of the present invention also provides a kind of preparation method of the drug of above-mentioned treatment neurodermatitis.
In order to improve the curative effect for the drug for treating neurodermatitis, there are infection conditions after preventing patient's use, sterile
After mixing shakes up after area extracts vitamin B complex, calcium colloidal et vit D, chlorpheniramine, dexamethasone acetate, Triamcinolone acetonide by needle tubing
The drug for the treatment of neurodermatitis can be obtained.
Feature and performance of the invention are described in further detail with reference to embodiments.
Embodiment 1
The present embodiment provides a kind of drug for treating neurodermatitis, the drug of the treatment neurodermatitis mainly include with
Lower raw material:
Vitamin B12 0.01g, calcium colloidal et vit D 0.05g, chlorpheniramine 0.003g, dexamethasone acetate 0.001g, Qu An
How moral 0.002g.
The drug of the treatment neurodermatitis the preparation method is as follows:
Under normal temperature and pressure conditions, by vitamin B12 0.01g, calcium colloidal et vit D 0.05g, chlorpheniramine 0.003g, acetic acid
Addition emulsion-type matrix, which stirs evenly, after dexamethasone 0.001g, Triamcinolone acetonide 0.002g mixing can be obtained treatment nerve skin
Scorching drug.
Wherein, the dosage form of the drug for the treatment of neurodermatitis provided in this embodiment is emulsion bases ointment.
Embodiment 2
The present embodiment provides a kind of drug for treating neurodermatitis, the drug of the treatment neurodermatitis mainly include with
Lower raw material:
Vitamin B12 0.5g, calcium colloidal et vit D 0.3g, chlorpheniramine 0.01g, dexamethasone acetate 0.005g, Triamcinolone acetonide
0.008g。
The drug of the treatment neurodermatitis the preparation method is as follows:
By vitamin B12 0.5g, calcium colloidal et vit D 0.3g, chlorpheniramine 0.01g, dexamethasone acetate 0.005g, Qu An how
The drug for the treatment of neurodermatitis can be obtained after moral 0.008g mixing.
Wherein, the dosage form of the drug for the treatment of neurodermatitis provided in this embodiment is injection.
Embodiment 3
The present embodiment provides a kind of drug for treating neurodermatitis, the drug of the treatment neurodermatitis mainly include with
Lower raw material:
Vitamin B12 0.2g, calcium colloidal et vit D 0.1g, chlorpheniramine 0.005g, dexamethasone acetate 0.003g, Qu An how
Moral 0.005g.
The drug of the treatment neurodermatitis the preparation method is as follows:
By vitamin B12 0.2g, calcium colloidal et vit D 0.1g, chlorpheniramine 0.005g, dexamethasone acetate 0.003g, Qu An
How moral 0.005g mixing after can be obtained treatment neurodermatitis drug.
Wherein, the dosage form of the drug for the treatment of neurodermatitis provided in this embodiment is injection.
Embodiment 4
The present embodiment provides a kind of drug for treating neurodermatitis, the drug of the treatment neurodermatitis mainly include with
Lower raw material:
Vitamin B1 0.01g, calcium colloidal et vit D 0.05g, chlorpheniramine 0.003g, dexamethasone acetate 0.001g, Qu An how
Moral 0.002g.
The drug of the treatment neurodermatitis the preparation method is as follows:
In aseptic area by vitamin B1 0.01g, calcium colloidal et vit D 0.05g, chlorpheniramine 0.003g, dexamethasone acetate
The drug for the treatment of neurodermatitis can be obtained in mixing after 0.001g, Triamcinolone acetonide 0.002g are extracted by needle tubing after shaking up.
Wherein, the dosage form of the drug for the treatment of neurodermatitis provided in this embodiment is injection.
Embodiment 5
The present embodiment provides a kind of drug for treating neurodermatitis, the drug of the treatment neurodermatitis mainly include with
Lower raw material:
Vitamin B1 0.5g, calcium colloidal et vit D 0.3g, chlorpheniramine 0.01g, dexamethasone acetate 0.05g, Triamcinolone acetonide
0.08g。
The drug of the treatment neurodermatitis the preparation method is as follows:
Aseptic area by vitamin B1 0.5g, calcium colloidal et vit D 0.3g, chlorpheniramine 0.01g, dexamethasone acetate 0.05g,
The drug for the treatment of neurodermatitis can be obtained in mixing after Triamcinolone acetonide 0.08g is extracted by needle tubing after shaking up.
Wherein, the dosage form of the drug for the treatment of neurodermatitis provided in this embodiment is injection.
Embodiment 6
The present embodiment provides a kind of drug for treating neurodermatitis, the drug of the treatment neurodermatitis mainly include with
Lower raw material:
Vitamin B1 0.225g, calcium colloidal et vit D 0.175g, chlorpheniramine 0.0065g, dexamethasone acetate 0.003g, song
An Naide 0.041g.
The drug of the treatment neurodermatitis the preparation method is as follows:
Under normal temperature and pressure conditions, by vitamin B1 0.225g, calcium colloidal et vit D 0.175g, chlorpheniramine 0.0065g, vinegar
Addition emulsion-type matrix, which stirs evenly, after sour dexamethasone 0.003g, Triamcinolone acetonide 0.041g mixing can be obtained treatment nerve
The drug of dermatitis.
Wherein, the dosage form of the drug for the treatment of neurodermatitis provided in this embodiment is emulsion bases ointment.
Embodiment 7
The present embodiment provides a kind of drug for treating neurodermatitis, the drug of the treatment neurodermatitis mainly include with
Lower raw material:
Vitamin B12 0.005g, it vitamin B1 0.005g, calcium colloidal et vit D 0.3g, chlorpheniramine 0.003g, fills in acetic acid
Rice pine 0.001g, Triamcinolone acetonide 0.002g.
The drug of the treatment neurodermatitis the preparation method is as follows:
By vitamin B12 0.005g, vitamin B1 0.005g, calcium colloidal et vit D 0.3g, chlorpheniramine 0.003g, acetic acid
The drug for the treatment of neurodermatitis can be obtained after Sai meter Song 0.001g, Triamcinolone acetonide 0.002g mixing.
Wherein, the dosage form of the drug for the treatment of neurodermatitis provided in this embodiment is injection.
Embodiment 8
The present embodiment provides a kind of drug for treating neurodermatitis, the drug of the treatment neurodermatitis mainly include with
Lower raw material:
Vitamin B12 0.01g, calcium colloidal et vit D 0.05g, chlorpheniramine 0.003g, dexamethasone acetate 0.001g, Qu An
How moral 0.008g, hydrocortisone 0.001g.
The drug of the treatment neurodermatitis the preparation method is as follows:
By vitamin B12 0.01g, calcium colloidal et vit D 0.05g, chlorpheniramine 0.003g, dexamethasone acetate 0.001g, song
The drug for the treatment of neurodermatitis can be obtained after An Naide 0.008g, hydrocortisone 0.001g mixing.
Wherein, the dosage form of the drug for the treatment of neurodermatitis provided in this embodiment is injection.
Embodiment 9
The present embodiment provides a kind of drug for treating neurodermatitis, the drug of the treatment neurodermatitis mainly include with
Lower raw material:
Vitamin B12 0.5g, calcium colloidal et vit D 0.3g, chlorpheniramine 0.01g, dexamethasone acetate 0.005g, Triamcinolone acetonide
0.008g, hydrocortisone 0.008g, cetirizine 0.002g.
The drug of the treatment neurodermatitis the preparation method is as follows:
By vitamin B12 0.5g, calcium colloidal et vit D 0.3g, chlorpheniramine 0.01g, dexamethasone acetate 0.005g, Qu An how
Treatment can be obtained after shaking up in mixing after moral 0.008g, hydrocortisone 0.008g, cetirizine 0.002g are extracted by needle tubing
The drug of neurodermatitis.
Wherein, the dosage form of the drug for the treatment of neurodermatitis provided in this embodiment is injection.
Embodiment 10
The present embodiment provides a kind of drug for treating neurodermatitis, the drug of the treatment neurodermatitis mainly include with
Lower raw material:
Vitamin B12 0.25g, vitamin B1 0.25g, calcium colloidal et vit D 0.3g, chlorpheniramine 0.01g, acetic acid rice is filled in
Loose 0.001g, Triamcinolone acetonide 0.005g, hydrocortisone 0.045g, cetirizine 0.006g, doxepin 0.0065g, benefit card
Because of 0.005g.
The drug of the treatment neurodermatitis the preparation method is as follows:
By vitamin B12 0.25g, vitamin B1 0.25g, calcium colloidal et vit D 0.3g, chlorpheniramine 0.01g, fill in acetic acid
Rice pine 0.001g, Triamcinolone acetonide 0.005g, hydrocortisone 0.045g, cetirizine 0.006g, doxepin 0.0065g, benefit
Emulsion-type matrix is added after cacaine 0.005g mixing and stirs evenly the drug that treatment neurodermatitis can be obtained.
Wherein, the dosage form of the drug for the treatment of neurodermatitis provided in this embodiment is emulsion bases ointment.
Embodiment 11
The present embodiment provides a kind of drug for treating neurodermatitis, the drug of the treatment neurodermatitis mainly include with
Lower raw material:
Vitamin B12 0.2g, calcium colloidal et vit D 0.1g, chlorpheniramine 0.005g, dexamethasone acetate 0.003g, Qu An how
Moral 0.005g, doxepin 0.0125g, cetirizine 0.01g, lidocaine 0.01g.
The drug of the treatment neurodermatitis the preparation method is as follows:
By vitamin B12 0.2g, calcium colloidal et vit D 0.1g, chlorpheniramine 0.005g, dexamethasone acetate 0.003g, Qu An
How moral 0.005g, doxepin 0.0125g, cetirizine 0.01g, lidocaine 0.01g by needle tubing extract after mixing shake up after
The drug for the treatment of neurodermatitis can be obtained.
Wherein, the dosage form of the drug for the treatment of neurodermatitis provided in this embodiment is injection.
Comparative example
This comparative example provides a kind of compound Kin White of commercially available treatment neurodermatitis, specification 15g, production enterprise
Industry is Sino-U.S. Shanghai Shi Guibao pharmaceutical Co. Ltd, spare.
Test example
It causes to itch as model with mouse histamine phosphate, the drug of the treatment neurodermatitis prepared in testing example 1~5
The influence of reaction of itching is caused to histamine phosphate with compound Kin White commercially available in comparative example.
Test method is as follows:
The mouse of 7 week old is bought, male and female have both.Laboratory rearing after a week, mouse is randomly divided into 7 groups, every group 10
Only, wherein one group is blank control group.Test proxima luce (prox. luc), dorsal portion shaving after each test group mouse is right, area about 2cm × 2cm
Then at shaving area medication 1 time.The same day is tested, with instep shaving area behind the coarse sandpaper scratch right side, medication is primary again for part, every every time
Mouse dosage is about 0.1g.Each group starts to drip 0.01% phosphorus at the dorsal portion surface of a wound behind the right side 10 minutes after last medication
Sour histamine 0.05ml/, hereafter at intervals of two minutes according to 0.01%, 0.02%, 0.03%, 0.04%...... progressive concentration, often
It is secondary be 0.05ml/ only, it is to be administered when mouse later licks right metapedes finally to occur until mouse occur later licks right metapedes
Histamine phosphate's total amount (μ g) is itch-threshold.Itch-threshold according to each group mouse evaluates the itching-relieving action of the test medicine, as a result
It is shown in Table 1.
1. Examples 1 to 5 of table, comparative example, blank control group cause the influence of reaction of itching to histamine phosphate
Through table it is observed that compared with comparative example, prepared by Examples 1 to 3, embodiment 5 and embodiment 11
The drug for treating neurodermatitis can significantly improve histamine phosphate and cause the itch-threshold of reaction of itching to mouse local skin, with blank
Control group compares with significant difference.Meanwhile by embodiment 2 and 5 experimental result of embodiment it is known that in other components
Dosage is identical and when being all injection, and the itching-relieving action wanted of drug of the treatment neurodermatitis prepared with vitamin B12 is higher than
With the drug for the treatment of neurodermatitis prepared by vitamin B1.
Embodiments described above is a part of the embodiment of the present invention, instead of all the embodiments.Reality of the invention
The detailed description for applying example is not intended to limit the range of claimed invention, but is merely representative of selected implementation of the invention
Example.Based on the embodiments of the present invention, obtained by those of ordinary skill in the art without making creative efforts
Every other embodiment, shall fall within the protection scope of the present invention.
Claims (10)
1. a kind of drug for treating neurodermatitis, which is characterized in that including following components according to parts by weight:
0.01~0.5 part of vitamin B complex, 0.003~0.01 part of chlorpheniramine, fills in rice to acetic acid at 0.05~0.3 part of calcium colloidal et vit D
0.001~0.005 part, 0.002~0.008 part of Triamcinolone acetonide of pine.
2. the drug for the treatment of neurodermatitis according to claim 1, which is characterized in that the vitamin B complex includes dimension
Raw element B12 and/or vitamin B1.
3. the drug for the treatment of neurodermatitis according to claim 2, which is characterized in that including according to parts by weight with
Lower component:
How are 0.2 part of vitamin B12,0.1 part of calcium colloidal et vit D, 0.005 part of chlorpheniramine, 0.003 part of dexamethasone acetate, Qu An
0.005 part of moral.
4. the drug for the treatment of neurodermatitis according to claim 1, which is characterized in that the treatment neurodermatitis
Drug further includes 0.001~0.008 part of hydrocortisone according to parts by weight.
5. the drug for the treatment of neurodermatitis according to claim 4, which is characterized in that the treatment neurodermatitis
Drug further includes 0.002~0.01 part of cetirizine according to parts by weight.
6. the drug for the treatment of neurodermatitis according to claim 5, which is characterized in that the treatment neurodermatitis
Drug further includes 0.005~0.0125 part of doxepin according to parts by weight.
7. the drug for the treatment of neurodermatitis according to claim 6, which is characterized in that the treatment neurodermatitis
Drug further includes 0.005~0.01 part of lidocaine according to parts by weight.
8. the drug for the treatment of neurodermatitis according to claim 1-7, which is characterized in that the treatment nerve
The dosage form of the drug of property dermatitis includes injection.
9. a kind of preparation method of the drug of the described in any item treatment neurodermatitiss of such as claim 1-8, which is characterized in that
Including the vitamin B complex, the calcium colloidal et vit D, the chlorpheniramine, the dexamethasone acetate, the Triamcinolone acetonide are mixed
Close the drug that the treatment neurodermatitis can be obtained.
10. the preparation method of the drug for the treatment of neurodermatitis according to claim 9, which is characterized in that in aseptic area
The vitamin B complex, the calcium colloidal et vit D, the chlorpheniramine, the dexamethasone acetate, the Triamcinolone acetonide are passed through into needle
The drug of the treatment neurodermatitis can be obtained in mixing after pipe extracts after shaking up.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910621479.3A CN110327319A (en) | 2019-07-10 | 2019-07-10 | A kind of drug and preparation method thereof for treating neurodermatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910621479.3A CN110327319A (en) | 2019-07-10 | 2019-07-10 | A kind of drug and preparation method thereof for treating neurodermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110327319A true CN110327319A (en) | 2019-10-15 |
Family
ID=68146215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910621479.3A Pending CN110327319A (en) | 2019-07-10 | 2019-07-10 | A kind of drug and preparation method thereof for treating neurodermatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110327319A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4104814A1 (en) * | 2021-06-15 | 2022-12-21 | DSM IP Assets B.V. | Novel use of vitamin b12 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709266A (en) * | 2005-06-17 | 2005-12-21 | 王贵玉 | Ointment for treating skin disease and its production method |
| CN1943581A (en) * | 2006-10-20 | 2007-04-11 | 刘亚军 | External use medicine for treating dermatosis and its preparing method |
| JP2007106723A (en) * | 2005-10-15 | 2007-04-26 | Taisho Pharmaceut Co Ltd | Kit for treating atopic dermatitis |
| CN101264070A (en) * | 2008-04-25 | 2008-09-17 | 梁勇才 | Dermatosis-treating medicine and preparation thereof |
| CN101406476A (en) * | 2007-10-11 | 2009-04-15 | 杨继荣 | Agent for treating skin peeling and allergy |
-
2019
- 2019-07-10 CN CN201910621479.3A patent/CN110327319A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709266A (en) * | 2005-06-17 | 2005-12-21 | 王贵玉 | Ointment for treating skin disease and its production method |
| JP2007106723A (en) * | 2005-10-15 | 2007-04-26 | Taisho Pharmaceut Co Ltd | Kit for treating atopic dermatitis |
| CN1943581A (en) * | 2006-10-20 | 2007-04-11 | 刘亚军 | External use medicine for treating dermatosis and its preparing method |
| CN101406476A (en) * | 2007-10-11 | 2009-04-15 | 杨继荣 | Agent for treating skin peeling and allergy |
| CN101264070A (en) * | 2008-04-25 | 2008-09-17 | 梁勇才 | Dermatosis-treating medicine and preparation thereof |
Non-Patent Citations (3)
| Title |
|---|
| 中国人民解放军第二军医大学药学系: "《药剂学（上册）》", 31 January 1981 * |
| 陈咏玫: "《孕期营养同步指导大全》", 31 May 2012, 中国轻工业出版社 * |
| 陈志伟: "《外阴肛周皮肤病中西医特色治疗》", 31 July 2013, 浙江科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4104814A1 (en) * | 2021-06-15 | 2022-12-21 | DSM IP Assets B.V. | Novel use of vitamin b12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005129267A (en) | DRUGS FOR TRANSMISSION AND TRANSMISIONAL DELIVERY | |
| US20060135599A1 (en) | Use for pharmaceutical composition | |
| WO2008148303A1 (en) | A composition for treating vegetative dystonine syndrome and pharmaceutical preparation and application thereof | |
| DE60111025T2 (en) | Use of topiramate for the treatment and diagnosis of respiratory disorders during sleep and means for performing the treatment and diagnosis | |
| EP2974733B1 (en) | Combination of valerian root extract and lavender oil for use in the treatment of sleep disorders | |
| CN110327319A (en) | A kind of drug and preparation method thereof for treating neurodermatitis | |
| EP1796702B1 (en) | Use of lavender oil for the prophylaxis and treatment of somatization disorders and posttraumatic stress disorder | |
| CN109700939A (en) | Dendrobium candidum leaf, rhizoma polygonati and radish seed are applied in preparation treatment hypertension drug | |
| CN104248722A (en) | Medicament for treating female hypersexuality | |
| Dogan et al. | A miracle that accelerates operating room functionality: sugammadex | |
| CN104606504A (en) | External plaster for treating the gastric ulcer | |
| CN101926890B (en) | Medicament for treating xerophthalmia | |
| CN103356939A (en) | Medicine for treatment of enuresis and its preparation method | |
| DE60133284T2 (en) | MEDICAL COMBINATION PREPARATION FOR THE TREATMENT OF INJURED ABNORMAL TISSUE | |
| JP2006219380A (en) | Glycyrrhizin subcutaneous injection preparation | |
| CN103989685A (en) | Preparation method of compound lamotrigine subcutaneous implantable controlled-release glue rod | |
| CN102784226A (en) | External Chinese medicine preparation for realizing postoperative analgesia and promoting wound healing and preparation method of external Chinese medicine preparation | |
| CN107050393A (en) | Numbness of relaxing dispersing paste and preparation method and application | |
| CN116688058B (en) | Li medicine for impotence, preparation method and application thereof | |
| Okur et al. | Effects of bupivacaine infiltration on beta-endorphin and cortisol release and postoperative pain following inguinal herniorrhaphy in children | |
| CN102793787B (en) | Traditional Chinese medicine ointment for postoperative analgesia and wound healing promotion, and preparation method thereof | |
| CN106309974A (en) | Traditional chinese medicine composition | |
| Alipour et al. | Comparison of Analgesic Effects of B Vitamins and Diclofenac plus B Vitamins During General Anesthesia and PACU | |
| CN106421422A (en) | Traditional Chinese medicine composition for curing insomnia | |
| CN102327318A (en) | Application of rubescensine in preparation of drug for preventing and treating osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191015 |